Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

eli lilly and company limited  - fentanyl - nervous system - dogs - for the control of pain associated with orthopaedic and soft tissue surgery in dogs.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

eli lilly and company (ireland) limited - ixekizumab - psoriasis - immunosuppressants - plaque psoriasistaltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.psoriatic arthritistaltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (dmard) therapies.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

eli lilly nederland b.v. - dulaglutide - diabetes mellitus, type 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.for study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - digoxin-specific antibody fragment f(ab) (ovine), quantity: 40 mg - injection, powder for - excipient ingredients: mannitol; sodium acetate - digoxin-specific antibody fragment f(ab) (ovine) digifab is indicated for the treatment of known (or strongly suspected) life-threatening digoxin toxicity associated with ventricular arrhythmias, progressive bradycardia, or second or third degree heart block not responsive to atropine, and where additional measures besides withdrawal of digoxin and correction of serum electrolyte abnormalities are considered necessary. consequences of multiple dosing with digifab have not been evaluated.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

eli lilly nederland b.v. - glucagon - diabetes mellitus - pancreatic hormones, glycogenolytic hormones - baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastic agents - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

eli lilly nederland b.v. - tirzepatide - diabetes mellitus, type 2 - drugs used in diabetes - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes.for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

eli lilly nederland b.v. - lasmiditan succinate - migraine disorders - analgesics - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

pfizer ltd. - sitaxentan sodium - hypertension, pulmonary - antihypertensives, - treatment of patients with pulmonary arterial hypertension (pah) classified as who functional class iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methylnaltrexone bromide, quantity: 12 mg - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; sodium calcium edetate; glycine hydrochloride; water for injections; sodium chloride - relistor is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care when response to laxative therapy has not been sufficient.